Key Takeaways
- Sector: Healthcare Healthtech & Medtech.
- Geography: United States.
Analysis
GTCR has announced the closing of a structured minority equity investment of up to $200 million in Solmetex, a leading U.S. dental technology and dental supplies company. This backing is designed to support both organic growth and a pipeline of add-on acquisitions globally.
Solmetex, founded in 1994 and headquartered in the U.S., is best known for its amalgam separation, dental waterline safety, dental isolation solutions, and regenerative biomaterials. Today, Solmetex serves over 85,000 dental offices throughout the United States. Over time, it has expanded beyond its original remit of mercury waste removal to offer a full suite of dental water and consumables solutions.
GTCR will partner with Solmetex’s existing investors, including AGIC Capital, and the current management team led by CEO Gene Dorff, bringing sector knowledge and capital flexibility to help scale operations. The investment is structured in stages and may be fully deployed as growth milestones are achieved.
Luke Marker, Managing Director at GTCR, commented: “Solmetex is uniquely positioned in the dental supply chain. We look forward to helping accelerate its next phase of growth across the U.S. and potentially international markets.” Jason Prager, also a Managing Director, added that GTCR’s capital and strategic insight will support value creation alongside the management team.
This deal follows Solmetex’s previous sale in March 2025 when Avista Healthcare sold the company to AGIC Capital, with Avista retaining a minority stake. Under Avista’s oversight, Solmetex expanded through three acquisitions: Sterisil, Dryshield, and Impladent, strengthening its product portfolio and competitive positioning. (Note: this new GTCR round represents a continuation of that growth trajectory.)
In recent years, GTCR has shown strong activity in the healthcare and life sciences sectors. For example, the firm made a $200 million preferred-equity investment in Telus Health for its Workplace Options acquisition, and it has acquired medical device companies such as Surmodics. The firm continues to emphasize “The Leaders Strategy”, which pairs deep domain expertise with disciplined capital deployment.
As private equity interest in healthcare accelerates worldwide—especially in medical supply, services, diagnostics, and technology—GTCR’s move into dental consumables underscores the appeal of high-margin, regulation-driven niches. Global trends show PE fundraising and deal volumes increasing sharply in healthcare, particularly in North America and Europe.
By working alongside Solmetex’s management and existing investors, GTCR aims to advance geographic expansion (potentially beyond the U.S.), broaden the product platform, and execute value-accretive acquisitions. This strategic investment strengthens Solmetex’s ability to compete, innovate, and grow in a rapidly evolving dental and medical consumables marketplace.